Cargando…

How health technology reassessment can support disinvestment in China’s national drug reimbursement list

A requirement to assess actual use of reimbursed medicines would enable transparent, documented, evidence based decisions on disinvestment, say Lizheng Shi and colleagues

Detalles Bibliográficos
Autores principales:	Shi, Lizheng, Wu, Jiuhong, Meng, Qingyue, Li, Dakui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2023
Materias:	Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266436/ https://www.ncbi.nlm.nih.gov/pubmed/37321624 http://dx.doi.org/10.1136/bmj-2021-068917

Ejemplares similares

Rational use of antibiotics in the context of China’s health system reform
por: He, Ping, et al.
Publicado: (2019)

Use of health technology assessment in drug reimbursement decisions in China
por: Chen, Wen, et al.
Publicado: (2023)

Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list
por: Liu, Liu, et al.
Publicado: (2022)

Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy
por: Chen, Yingyao, et al.
Publicado: (2023)

Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List
por: Liu, Wenbin, et al.
Publicado: (2019)

What can we learn from China’s health system reform?
por: Meng, Qingyue, et al.
Publicado: (2019)

Using economic evaluations to support acupuncture reimbursement decisions: current evidence and gaps
por: Li, Hongchao, et al.
Publicado: (2022)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
por: Macabeo, Bérengère, et al.
Publicado: (2023)

Are overwhelmed health systems an inevitable consequence of covid-19? Experiences from China, Thailand, and New York State
por: Tangcharoensathien, Viroj, et al.
Publicado: (2021)

From response to transformation: how countries can strengthen national pandemic preparedness and response systems
por: Haldane, Victoria, et al.
Publicado: (2021)

Fibre intake for optimal health: how can healthcare professionals support people to reach dietary recommendations?
por: McKeown, Nicola M, et al.
Publicado: (2022)

Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017)

Differences in reimbursement listing of anticancer therapies in China: an observational study
por: Guan, Xiaodong, et al.
Publicado: (2020)

Critical Appraisal of Reimbursement List in Bosnia and Herzegovina
por: Mujkic, Sabina, et al.
Publicado: (2017)

What influences the outcome of active disinvestment processes in healthcare? A qualitative interview study on five recent cases of active disinvestment
por: Rotteveel, Adriënne H., et al.
Publicado: (2021)

WHO and national lists of essential medicines in Mexico, Central and South America, and the Caribbean: are they adequate to promote paediatric endocrinology and diabetes care?
por: Rowlands, Amanda, et al.
Publicado: (2016)

How healthcare can help heal communities and the planet
por: Francis, Damon, et al.
Publicado: (2019)

Impact of delisting OTC medicines from reimbursement list
por: Chytilová, Petra, et al.
Publicado: (2015)

Containing medical expenditure: lessons from reform of Beijing public hospitals
por: Liu, Xiaoyun, et al.
Publicado: (2019)

Health Technology Reassessment: Addressing Uncertainty in Economic Evaluations of Oncology Drugs at Time of Reimbursement Using Long-Term Clinical Trial Data
por: Ball, Graeme, et al.
Publicado: (2023)

How can we realise the full potential of health systems for nutrition?
por: Heidkamp, Rebecca A, et al.
Publicado: (2020)

How can WHO transform its approach to social determinants of health?
por: Gopinathan, Unni, et al.
Publicado: (2022)

Can nutrition support healthy cognitive ageing and reduce dementia risk?
por: Jennings, Amy, et al.
Publicado: (2020)

Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study
por: Zhu, Hong, et al.
Publicado: (2022)

Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis
por: Yi, Hongbin, et al.
Publicado: (2023)

How can countries create outbreak response policies that are sensitive to maternal health?
por: Takemoto, Maira L S, et al.
Publicado: (2021)

Reorienting programme budgeting and marginal analysis (PBMA) towards disinvestment
por: Mortimer, Duncan
Publicado: (2010)

FROM TALK TO ACTION: POLICY STAKEHOLDERS, APPROPRIATENESS, AND SELECTIVE DISINVESTMENT
por: Paprica, P. Alison, et al.
Publicado: (2015)

Tailored support for national NCD policy and programme implementation: an over-looked priority
por: Jackson-Morris, Angela, et al.
Publicado: (2020)

From blockchain technology to global health equity: can cryptocurrencies finance universal health coverage?
por: Till, Brian M, et al.
Publicado: (2017)

Using the WHO Essential Medicines List to Assess the Appropriateness of Insurance Coverage Decisions: A Case Study of the Croatian National Medicine Reimbursement List
por: Jeličić Kadić, Antonia, et al.
Publicado: (2014)

Reporting quality of economic evaluations of the negotiated Traditional Chinese Medicines in national reimbursement drug list of China: A systematic review
por: Yan, Juntao, et al.
Publicado: (2023)

Business not as usual: how multisectoral collaboration can promote transformative change for health and sustainable development
por: Kuruvilla, Shyama, et al.
Publicado: (2018)

Developing a How-to-Guide for Health Technology Reassessment: "The HTR Playbook"
por: Soril, Lesley J.J., et al.
Publicado: (2021)

Armed conflicts and national trends in reproductive, maternal, newborn and child health in sub-Saharan Africa: what can national health surveys tell us?
por: Boerma, Ties, et al.
Publicado: (2019)

Disinvestment in the presence of uncertainty: Description of a novel, multi-group, disinvestment trial design and protocol for an application to reduce or cease use of mobilisation alarms for preventing falls in hospitals
por: Haines, Terry P., et al.
Publicado: (2021)

Disinvestment policy and the public funding of assisted reproductive technologies: outcomes of deliberative engagements with three key stakeholder groups
por: Hodgetts, Katherine, et al.
Publicado: (2014)

Moving low value care lists into action: prioritizing candidate health technologies for reassessment using administrative data
por: Soril, Lesley J. J., et al.
Publicado: (2018)

Artificial intelligence (AI) and global health: how can AI contribute to health in resource-poor settings?
por: Wahl, Brian, et al.
Publicado: (2018)

Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level
por: Calabrò, G. E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1g4f7dvhupfh86li3j8ifljuo6